GAITHERSBURG, MD--(Marketwired - Sep 28, 2015) - Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that CEO Bill Enright will present at the 2015 Ladenburg Thalmann Healthcare Conference to be held tomorrow at the Sofitel Hotel in New York City. Enright's presentation will take place at 11:30am ET.

For information on Ladenburg Thalmann, please visit

About Altimmune
Altimmune is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary platform technologies, Altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. Our Densigen™ T-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual's immune system against multiple target antigens instead of just one. Altimmune's RespirVec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. Altimmune's product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current products.

Contact Information:

Altimmune Contact
Bill Enright
President and CEO
Phone: 240-654-1450